Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices
Houston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR, Judge DP, Russell SD, Rouf R. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. The Journal Of Heart And Lung Transplantation 2016, 36: 380-385. PMID: 28169115, DOI: 10.1016/j.healun.2016.12.016.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceGastrointestinal bleedingAngiotensin II antagonismARB therapyVascular endothelial growth factorArteriovenous malformationsVentricular assist deviceAssist deviceAngiotensin receptor blocker therapyContinuous-flow Left Ventricular Assist DevicesAssociation of ACEIReceptor blocker therapyInternational normalized ratioRegression hazard modelGastrointestinal arteriovenous malformationsJohns Hopkins HospitalLogistic regression analysisRisk of AVMAngiotensin II SignalingEndothelial growth factorBlocker therapyRenal functionAdult patientsBlood pressureCardiomyopathy etiology